Navigation Links
Aton Pharma Announces the Appointment of Dr. Fred Eshelman to Management Board

LAWRENCEVILLE, N.J., Feb. 25 /PRNewswire/ -- Aton Pharma, Inc., a global specialty pharmaceutical company, announced today that Dr. Fred Eshelman has joined the management board of Aton's parent company, Princeton Pharma Holdings LLC. Dr. Eshelman is the founder, Vice Chairman and CEO of Pharmaceutical Product Development, Inc. (Nasdaq: PPDI), an international contract research organization. Aton is a wholly owned subsidiary of Princeton Pharma Holdings LLC.

"We are delighted that Dr. Eshelman has agreed to join Princeton Pharma Holdings' management board," said Michael G. Wells, Chief Executive Officer of Aton Pharma. "He is a rare individual -- both an accomplished entrepreneur and an accomplished scientist. He built a very successful enterprise from the ground up and his knowledge of product development is exceptional. His insights are going to provide tremendous value to Aton as we implement our strategic plan."

"Aton is a very interesting specialty pharmaceutical company with their focus on medically essential therapeutics and I'm impressed with the amount of progress they have made in a relatively short period of time," stated Dr. Eshelman. "I look forward to lending my experience and helping this company reach its goals."

Dr. Eshelman's expertise will be helpful as Aton continues to execute its product life cycle management strategy and expand its research program, which includes partnerships with a variety of thought leaders, major medical institutions and research organizations.

Dr. Eshelman's career has included positions as Senior Vice President of Development and Vice President of Clinical Operations for the former Glaxo, Inc., as well as various roles in drug development with other pharmaceutical companies. He received his doctorate in pharmacy from the University of Cincinnati and his bachelor's degree in pharmacy from the University of North Carolina at Chapel Hill. He is a graduate of the Owner President Management (OPM) program at Harvard Business School.

About Aton Pharma, Inc.

Aton Pharma, Inc., headquartered in Lawrenceville, NJ, is a global specialty pharmaceutical company providing essential treatments for under-treated diseases and rare illnesses around the world. Aton's mission is to improve patient outcomes and quality of life worldwide by enhancing and expanding access and availability of medically essential therapeutics. Aton's portfolio of seven products, with sales in over 30 countries, targets rare and orphan metabolic, neurological, cardiovascular and ophthalmic diseases. For more information, see

CONTACT Ed Stevens, 727-327-3396,

SOURCE Aton Pharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Strativa Pharmaceuticals, a Division of Par Pharmaceutical, Announces the Discontinuation of the Development Program for Pafuramidine
2. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results
3. AstraZeneca Response to February 21, 2008 Ruling In Re: Alabama Medicaid Pharmaceutical AWP Litigation - cv2005-219 - Circuit Court of Montgomery, Alabama
4. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2007 Financial Results on Monday, February 25, at 8:30 A.M. EST
5. Nycomed US Inc. Acquires Bradley Pharmaceuticals, Inc.
6. WuXi PharmaTech Schedules Fourth Quarter and Full Year 2007 Earnings Release on Wednesday, March 12, 2008
7. Genmab and PDL BioPharma Sign Purchase Agreement for Antibody Manufacturing Facility
8. Cadence Pharmaceuticals Completes $49.3 Million Registered Direct Offering
9. Addrenex Pharmaceuticals Reaches Milestone with Filing of NDA for First Product, CloniBID, to Treat Hypertension
10. Vion Pharmaceuticals to Implement a One-for-Ten Reverse Stock Split
11. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
Post Your Comments:
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, the only free ... and will showcase its product’s latest features from June 26 to June 30, ... poster on Disrupting Clinical Trials in The Cloud during the conference. DIA ...
(Date:6/23/2016)... ... June 23, 2016 , ... Velocity Products, a ... designed, tuned and optimized exclusively for Okuma CNC machining centers at The International ... a collaboration among several companies with expertise in toolholding, cutting tools, machining dynamics ...
(Date:6/23/2016)... , June 23, 2016 ... research report to its pharmaceuticals section with historic ... details and much more. Complete report ... 151 pages, profiling 15 companies and supported with ... . The Global ...
(Date:6/22/2016)... -- Research and Markets has announced the addition of ... offering. The global biomarkers ... in 2013. The market is expected to grow at a five-year ... increasing from $50.6 billion in 2015 to $96.6 billion in 2020. ... period (2015 to 2020) are discussed. As well, new products approved ...
Breaking Biology Technology:
(Date:4/15/2016)... 2016  A new partnership announced today will ... decisions in a fraction of the time it ... high-value life insurance policies to consumers without requiring ... Force Diagnostics, rapid testing (A1C, Cotinine and HIV) ... pressure, weight, pulse, BMI, and activity data) available ...
(Date:3/31/2016)... , March 31, 2016   ... ("LegacyXChange" or the "Company") LegacyXChange is excited ... of its soon to be launched online site for ... ) will also provide potential shareholders a ... DNA technology to an industry that is notorious for ...
(Date:3/22/2016)... India , March 22, 2016 /PRNewswire/ ... market research report "Electronic Sensors Market for Consumer ... Proximity, & Others), Application (Communication & IT, ... Geography - Global Forecast to 2022", published ... industry is expected to reach USD 26.76 ...
Breaking Biology News(10 mins):